The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Open accessAbstract
Background Patients with systemic lupus erythematosus have T-cell dysfunction that has been attributed to the activation of the mammalian target of rapamycin (mTOR). Rapamycin inhibits antigen-induced T-cell proliferation and has been developed as a medication under the generic designation of sirolimus. We assessed safety, tolerance, and efficacy of sirolimus in a prospective, biomarker-driven, open-label clinical trial.Methods We did a single-arm, open-label, phase 1/2 trial of sirolimus in patients with active systemic lupus erythematosus disease unresponsive to, or intolerant of, conventional medications at the State University of New York Upstate Medical University (Syracuse, NY, USA). Eligible participants (aged ≥18 years) had active systemic lupus erythematosus fulfilling four or more of 11 diagnostic criteria defined by the American College of Rheumatology. We excluded patients with allergy or intolerance to sirolimus, patients with life-threatening manifestations of systemic lupus erythematosus, proteinuria, a urine protein to creatinine ratio higher than 0·5, anaemia, leucopenia, or thrombocytopenia. Patients received oral sirolimus at a starting dose of 2 mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL. Patients were treated with sirolimus for 12 months. Safety outcomes included tolerance as assessed by the occurrence of common side-effects. The primary efficacy endpoint was decrease in disease activity, assessed using the British Isles Lupus Assessment Group (BILAG) index and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Blood samples of 56 matched healthy individuals were obtained as controls for immunobiological outcomes monitored at each visit. The primary efficacy endpoint was assessed in all patients who completed 12 months of treatment, and all patients who received at least one dose of treatment were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT00779194.Findings Between March 9, 2009, and Dec 8, 2014, 43 patients were enrolled, three of whom did not meet eligibility criteria. 11 of the 40 eligible patients discontinued study treatment because of intolerance (n=2) or non-compliance (n=9). SLEDAI and BILAG disease activity scores were reduced during 12 months of treatment in 16 (55%) of 29 patients who completed treatment. Mean SLEDAI score decreased from 10·2 (SD 5·6) at enrolment to 4·8 (4·5) after 12 months of treatment (p<0·001) and the mean total BILAG index score decreased from 28·4 (12·4) at enrolment to 17·4 (10·7) after 12 months of treatment (p<0·001). The mean daily dose of prednisone required to control disease activity decreased from 23·7 mg (SD 9·6) to 7·2 mg (2·3; p<0·001) after 12 months of treatment. Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months. CD8+ memory T cells were selectively expanded in SRI-responders. Patient liver function and lymphocyte counts were unchanged. Although HDL-cholesterol (Z=-2·50, p=0·012), neutrophil counts (Z=-1·92, p=0·054), and haemoglobin (Z=-2·83, p=0·005) were moderately reduced during treatment, all changes occurred within a range that was considered safe. Platelet counts were slightly elevated during treatment (Z=2·06, p=0·0400).Interpretation These data show that a progressive improvement in disease activity is associated with correction of pro-inflammatory T-cell lineage specification in patients with active systemic lupus erythematosus during 12 months of sirolimus treatment. Follow-up placebo-controlled clinical trials in diverse patient populations are warranted to further define the role of mTOR blockade in treatment of systemic lupus erythematosus.Funding Pfizer, the National Institutes of Health, and the Central New York Community Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, mTOR blockade in patients with SLE treated with N-acetylcysteine or rapamycin reduces both pro-inflammatory T cells and disease activity85,260, suggesting that dietary supplementation or drugs that regulate mitochondrial dynamics might constitute novel therapeutic avenues for mitigating autoantibody production in SLE.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [260]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
Tsokos, G. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,814
Navarra, S., Guzmán, R., Gallacher, A., Hall, S., Levy, R. A., Jimenez, R., Li, E. K., Thomas, M., Kim, H., Leon, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,078
Vézina, C., KUDELSKI, A., & Sehgal, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,691
Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis
Xia, J., & Wishart, D. S. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.11 · Cited by 1,560
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Cited by
Sorted by citations
Items 201–300 of 411
Liu, J., Zhang, B., Zhang, G., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1345838 · Cited by 21
Lactate and lactylation: emerging roles in autoimmune diseases and metabolic reprogramming
Liu, W., Yang, R., Zhan, Y., Yang, X., Zeng, H., Chen, B., Zeng, J., Hu, T., Hu, J., Xiao, Q., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1589853 · Cited by 21
Teng, X., Brown, J., & Morel, L. M. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0070 · Cited by 21
Wang, Y., Guo, H., Liang, Z., Feng, M., Wu, Y., Qin, Y., Zhao, X., Gao, C., Liu, G., & Luo, J. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.04.006 · Cited by 21
Cui, Y., Feng, Z., Zhao, Q., Dai, H., Yang, Z., Rui, H., & Liu, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713148 · Cited by 20
Age-related mechanisms in the context of rheumatic disease
Alsaleh, G., Richter, F. C., & Simon, A. K. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00863-8 · Cited by 20
Qin, L., Li, M., Tan, H.-L., Yang, H., Li, S.-D., Luan, Z.-X., Chen, Y., & Yang, M. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105790 · Cited by 22
CD8+ T Cell Phenotype and Function in Childhood and Adult-Onset Connective Tissue Disease
Radziszewska, A., Moulder, Z., Jury, E. C., & Ciurtin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911431 · Cited by 20
Shen, L., Zhong, X., Ji, H., Yang, S., Jin, J., Lyu, C., Ren, Y., Xiao, Y., Zhang, Y., Fang, S., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112590 · Cited by 19
A review of signaling and transcriptional control in T follicular helper cell differentiation
Hart, A. P., & Laufer, T. M. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ri0121-066r · Cited by 19
Expanding scope of TEMRA in autoimmunity
Perl, A., & Morel, L. M. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104520 · Cited by 19
Self-citationMinchenberg, S. B., Chaparala, G., Oaks, Z., Bánki, K., & Perl, A. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.07.007 · Cited by 19
Self-citationEffects of the mTOR and AKT genes polymorphisms on systemic lupus erythematosus risk
Saravani, M., Shahraki-Ghadimi, H., Maruei‐Milan, R., Mehrabani, M., Mirzamohammadi, S., & Nematollahi, M. H. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05446-y · Cited by 19
Liu, L., Takeda, K., & Akkoyunlu, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01569 · Cited by 19
Perry, D. J., Titov, A. A., Sobel, E. S., Brusko, T. M., & Morel, L. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108602 · Cited by 19
Katsuyama, E., Humbel, M., Suárez‐Fueyo, A., Satyam, A., Yoshida, N., Kyttaris, V. C., Tsokos, M., & Tsokos, G. C. (2024) · Nature Communications · doi:10.1038/s41467-024-52617-7 · Cited by 18
Ramón-Vázquez, A., Flood, P. F., Cashman, T. L., Patil, P., & Ghosh, S. K. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103735 · Cited by 18
Schank, M., Zhao, J., Wang, L., Nguyen, L. N. T., Cao, D., Dang, X., Khanal, S., Zhang, J., Zhang, Y., Wu, X. Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760707 · Cited by 19
Robinson, G., Pineda‐Torra, I., Ciurtin, C., & Jury, E. C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.914016 · Cited by 19
Zhang, J., Guo, Q., Dai, D., Yu, J. Y., Wang, L., Wu, Z., Ding, H., Shen, N., & Duan, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121766 · Cited by 18
Self-citationLiposomal aggregates sustain the release of rapamycin and protect cartilage from friction
Bordon, G., Ramakrishna, S. N., Edalat, S. G., Eugster, R., Arcifa, A., Vermathen, M., Aleandri, S., Frank‐Bertoncelj, M., Furrer, J., Vermathen, P., et al. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.07.087 · Cited by 18
Zhang, L., Du, F., Jin, Q., Sun, L. Q., Wang, B., Tan, Z., Meng, X., Huang, B., Zhan, Y., Su, W., et al. (2023) · Advanced Science · doi:10.1002/advs.202300123 · Cited by 18
Engineering metabolism to modulate immunity
Kapnick, S. M., Martin, C. A., & Jewell, C. M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115122 · Cited by 18
A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives
Han, Z., Ma, K., Tao, H., Liu, H., Zhang, J., Sai, X., Li, Y., Chi, M., Nian, Q., Song, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826732 · Cited by 21
Saadh, M. J., Kazemi, K., Khorramdelazad, H., Mousavi, M. J., Noroozi, N., Masoumi, M., & Karami, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110246 · Cited by 22
Schaier, M., Gottschalk, C., Uhlmann, L., Speer, C., Kälble, F., Eckstein, V., Müller‐Tidow, C., Meuer, S. C., Mahnke, K., Lorenz, H., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1778-6 · Cited by 17
Nakamura, M., Satoh, N., Horita, S., & Nangaku, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015204 · Cited by 19
Nguyen, L. N., Nguyen, L. N. T., Zhao, J., Schank, M., Dang, X., Cao, D., Khanal, S., Thakuri, B. K. C., Zhang, J., Lu, Z., et al. (2021) · Hepatology · doi:10.1002/hep.32008 · Cited by 16
Signaling by the inhibitory receptor CD200R is rewired by type I interferon
van der Vlist, M., Ramos, M. I. P., van den Hoogen, L. L., Hiddingh, S., Timmerman, L. M., de Hond, T. A. P., Kaan, E. D., van der Kroef, M., Lebbink, R. J., Peters, F., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abb4324 · Cited by 16
Abnormal energy metabolism in the pathogenesis of systemic lupus erythematosus
Cao, S., Jiang, J., Yin, H., Wang, L., & Lu, Q. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112149 · Cited by 16
Emerging targets for the treatment of lupus erythematosus: There is no royal road to treating lupus
Yasuda, S. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1493909 · Cited by 16
Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
Xing, L., Wang, Y., Liu, H., Gao, S., Shao, Q., Yue, L., Liu, Z., Wang, H., Shao, Z., & Fu, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.798352 · Cited by 16
Cytoplasmic RNA quality control failure engages mTORC1-mediated autoinflammatory disease
Yang, K., Han, J., Asada, M., Gill, J. G., Park, J. Y., Sathe, M., Gattineni, J., Wright, T., Wysocki, C., de la Morena, M. T., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci146176 · Cited by 16
Su, Q. Y., Luo, J., Wang, X., Di, J., Cao, Y., & Zhang, S. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1165 · Cited by 15
Ding, M., Jin, L., Zhao, J., Yang, L., Cui, S., Wang, X., He, J., Chang, F., Shi, M., Ma, J., et al. (2024) · Lupus Science & Medicine · doi:10.1136/lupus-2023-001072 · Cited by 15
Li, H., Zhou, L., Zhou, W., Zhang, X., Shang, J., Feng, X., Yu, L., Fan, J., Ren, J., Zhang, R., et al. (2024) · Rheumatology & autoimmunity · doi:10.1002/rai2.12119 · Cited by 15
Immune imbalance in Lupus Nephritis: The intersection of T-Cell and ferroptosis
Fan, Y., Ma, K., Lin, Y., Ren, J., Peng, H., Yuan, L., Nasser, M. I., Jiang, X., & Wang, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1520570 · Cited by 16
Li, W., Kolios, A. G. A., Pan, W., Burbano, C., Karino, K., Vichos, T., Humbel, M., Kyttaris, V. C., Tsokos, M., & Tsokos, G. C. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkag141.1774 · Cited by 15
Role of the mTOR signalling pathway in salivary gland development
Sakai, M., Fukumoto, M., Ikai, K., Minagi, H. O., Inagaki, S., Kogo, M., & Sakai, T. (2019) · FEBS Journal · doi:10.1111/febs.14937 · Cited by 15
Kato, H., & Perl, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635531 · Cited by 15
Self-citationImmunometabolic alterations in lupus: where do they come from and where do we go from there?
Ma, L., Roach, T., & Morel, L. M. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102245 · Cited by 15
Lúpus Eritematoso Sistêmico: relação entre os diferentes tratamentos e evolução clínica
Macedo, R. M., Garcia, T. ́., Castanheira, E. P., Noleto, D. C., Freitas, T. V. M., & Freitas, A. D. A. (2020) · Revista de Medicina · doi:10.11606/issn.1679-9836.v99i6p573-580 · Cited by 15
Park, J. S., & Perl, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310749 · Cited by 14
Self-citationImmunotherapeutic approaches for systemic lupus erythematosus: early overview and future potential
Huang, H. (2023) · Medical Review · doi:10.1515/mr-2023-0032 · Cited by 14
Metabolic Plasticity of Regulatory T Cells in Health and Autoimmunity
Carbone, F., Colamatteo, A., Rocca, C. L., Lepore, M. T., Russo, C., Rosa, G. D., Matarese, A., Procaccini, C., & Matarese, G. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400079 · Cited by 14
Overview of Oxidative Stress in Systemic Lupus Erythematosus
Lupu, A., Stoleriu, G., Nedelcu, A. H., Perju, S. N., Gavrilovici, C., Baciu, G., Mihai, C. M., Chisnoiu, T., Morariu, I. D., Grigore, E., et al. (2025) · Antioxidants · doi:10.3390/antiox14030303 · Cited by 17
Principles behind SLE treatment with N-acetylcysteine
Nasr, S., & Perl, A. (2022) · Immunometabolism · doi:10.1097/in9.0000000000000010 · Cited by 14
Self-citationHarder, J. W., Ma, J., Alard, P., Sokoloski, K. J., Mathiowitz, E., Furtado, S., Egilmez, N. K., & Kosiewicz, M. M. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiac002 · Cited by 14
Immunometabolomics provides a new perspective for studying systemic lupus erythematosus
Wu, Y., Zhao, M., Gong, N., Zhang, F., Chen, W., & Liu, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109946 · Cited by 14
Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis
Wang, Y., Zou, L., Xu, K., Xu, W., Zhang, M., Lu, Q., Tian, X., Pang, L.-Y., He, W., Wang, Q., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03243-5 · Cited by 13
Emerging Therapeutic Innovations for Vitiligo Treatment
Li, W., Dong, P., Zhang, G., Hu, J., & Yang, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030191 · Cited by 13
CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematosus
Fernández, D., & Crow, M. K. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30544-0 · Cited by 13
Amelioration of Lupus Serum-Induced Skin Inflammation in CD64-Deficient Mice
Jiang, L., Han, X., Qiu, W., Yu, T., Feng, R., Wang, X., Duan, X., & Deng, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.824008 · Cited by 13
Animal models of systemic lupus erythematosus and their applications in drug discovery
Xin, Y., Zhang, B., Zhao, J., Liu, Q., Yin, H., & Lu, Q. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2050691 · Cited by 14
mTOR Complex 1 Content and Regulation Is Adapted to Animal Longevity
Mota‐Martorell, N., Jové, M., & Pamplona, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158747 · Cited by 13
Zhang, Z., Hu, Q., Yang, C., Chen, M., & Han, B. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2282180 · Cited by 13
Perl, A. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.033 · Cited by 13
Self-citationYao, Y., Xu, H. J., Zhu, Y., Gong, Y., Song, X., Chen, J., Guo, N., Zhao, Y., Guo, J., Luo, X., et al. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103877 · Cited by 14
Essential metabolism required for T and B lymphocyte functions: an update
Diniz, V. L. S., Alvares-Saraiva, A. M., Serdan, T. D. A., dos Santos-Oliveira, L. C., Cruzat, V. F., Lobato, T. B., Manoel, R., Alecrim, A. L., Machado, O. A. S., Hirabara, S. M., et al. (2023) · Clinical Science · doi:10.1042/cs20220869 · Cited by 12
Liu, Y., Gao, Y., Zhao, H., Zhang, M., Duan, M., Li, J., & Zhang, L. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05783-z · Cited by 12
Du, B., Fan, X., Lei, F., Zhang, S., Li, G., & Xi, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106139 · Cited by 12
Datta, S. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.629807 · Cited by 12
Wang, D., Cassady, K. M., Zou, Z., Zhang, X., & Feng, Y. (2022) · Hematology · doi:10.1080/16078454.2022.2151230 · Cited by 12
Immunosenescence: Molecular Mechanisms, Diseases, and Therapeutic Innovations
Gong, N., Pan, X., Deng, Y., Che, J., Bao, J., Wang, M., Xu, C., Liu, X., & Shi, Y. (2025) · MedComm · doi:10.1002/mco2.70515 · Cited by 14
A global view of T cell metabolism in systemic lupus erythematosus
Goetz, A., Cagmat, J. G., Brusko, M., Brusko, T. M., Rushin, A., Merritt, M. E., Garrett, T. J., Morel, L. M., & Dixit, P. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371708 · Cited by 11
Intersection of the microbiome and immune metabolism in lupus
Garcia, A. C., Six, N., Ma, L., & Morel, L. M. (2024) · Immunological Reviews · doi:10.1111/imr.13360 · Cited by 12
Intricating connections: the role of ferroptosis in systemic lupus erythematosus
Zhao, G., Li, X., Zhang, Y., Wang, X., Deng, L., Xu, J., Jin, S., Zuo, Z., Xun, L., Luo, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1534926 · Cited by 11
Immunotargets and Therapy for Systemic Lupus Erythematosus
Mok, C. C. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485650 · Cited by 11
Iwata, S., & Tanaka, Y. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1964957 · Cited by 11
Successful treatment of sirolimus in a Chinese patient with refractory LN and APS: a case report
Zhang, D., Sun, F., & Ye, S. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221079253 · Cited by 11
Muñoz-Urbano, M., Quintero-González, D. C., & Vásquez, G. M. (2022) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2055568 · Cited by 11
Fallone, L., Walzer, T., & Marçais, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612736 · Cited by 13
González-Moret, Y. A., Lo, K. B., & Tan, I. J. (2024) · ACR Open Rheumatology · doi:10.1002/acr2.11698 · Cited by 11
Olson, W. J., Jakic, B., & Hermann‐Kleiter, N. (2020) · FEBS Journal · doi:10.1111/febs.15312 · Cited by 11
Liu, Y., & Yang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1443440 · Cited by 11
Myeloid cells as IFNα producers in systemic lupus erythematosus
Kuga, T., Chiba, A., Murayama, G., & Miyake, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1562221 · Cited by 10
Regulating T Cell Population Alleviates SLE by Inhibiting mTORC1/C2 in MRL/lpr Mice
Zhang, D., Wang, M., Shi, G., Pan, P., Ji, J., & Li, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.579298 · Cited by 10
Jain, V., Bose, S. N., Arya, A. K., & Arif, T. (2022) · Cancers · doi:10.3390/cancers14071618 · Cited by 10
RetractedBreaking Glycolysis Barriers to Immunotherapy with Nanomedicines
Zhang, M., Ren, Y., Li, J., Yu, J., Li, Q., Zhao, H., Wang, Z., Chen, X. S., & Cheng, J. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00042 · Cited by 9
Self-citationEndosome traffic in rheumatic diseases: mechanistic insights and therapeutic opportunities
Perl, A. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01336-4 · Cited by 9
Self-citationUrine Metabolic Fingerprints Encode Subtypes of Kidney Diseases
Yang, J., Wang, R., Huang, L., Zhang, M., Niu, J., Bao, C., Shen, N., Dai, M., Guo, Q., Wang, Q., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201913065 · Cited by 9
mTORC2 contributes to systemic autoimmunity
Zhou, X., Qi, H., Li, M., Li, Y., Zhu, X., Amin, S., Alexander, M. P., Diadhiou, C. M. M., Davidson, A., & Zeng, H. (2022) · Immunology · doi:10.1111/imm.13594 · Cited by 9
Beneficial effects of rapamycin on endothelial function in systemic lupus erythematosus
Kim, H., & Massett, M. P. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1446836 · Cited by 9
Shi, Y., Guan, S., Liu, X., Zhai, H., Zhang, Y., Liu, J., Yang, W., & Wang, Z. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70329 · Cited by 9
Shepshelovich, D., Yahav, D., Tibau, A., & Amir, E. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.08.009 · Cited by 10
Lindblom, J., Barturen, G., Beretta, L., Dominguez, D. T., Carnero‐Montoro, E., Borghi, M. O., Castillo, J., Iacobaeus, E., Enman, Y., Pers, J., et al. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100296 · Cited by 8
2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus
Zhao, J., Zhang, S., Wang, Q., Tian, X., Chen, Y., Li, M., & Zeng, X. (2025) · Rheumatology and Immunology Research · doi:10.1515/rir-2025-0017 · Cited by 8
Senescent CD4+ T cells and autoimmune diseases: mechanisms and therapeutic prospects
Hu, Y., He, L., & Long, H. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103957 · Cited by 10
Mao, Z., Tan, Y. C. R. S., Tao, J., Li, L., Yu, F., & Zhao, M. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.010 · Cited by 8
Mellouk, A., Hutteau-Hamel, T., Legrand, J., Safya, H., Benbijja, M., Mercier‐Nomé, F., Benihoud, K., Kanellopoulos, J., & Bobé, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957008 · Cited by 8
Advances in the pharmacological management of systemic lupus erythematosus
Tsoi, A., Nikolopoulos, D., & Parodis, I. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2354457 · Cited by 10
The dawn of a new era of therapies in systemic lupus erythematosus
Mok, C. C. (2020) · Rheumatology and Immunology Research · doi:10.2478/rir-2020-0005 · Cited by 8
Xu, B., Tang, J., Lyu, C., Wandu, W. S., Stumpo, D. J., Mattapallil, M. J., Horai, R., Gery, I., Blackshear, P. J., & Caspi, R. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583510 · Cited by 8
Evans, J. F., Rue, R. W., Mukhitov, A. R., Obraztsova, K., Smith, C. J., & Krymskaya, V. P. (2019) · Biomolecules · doi:10.3390/biom10010028 · Cited by 7
Banić, M., Pavliša, G., Hečimović, A., Grzelja, J., Anić, B., Samaržija, M., & Makek, M. J. (2023) · Rheumatology International · doi:10.1007/s00296-023-05363-w · Cited by 7
Mitochondria dysfunction: A trigger for cardiovascular diseases in systemic lupus erythematosus
Wang, H., Tang, R., Pan, Q., Yin, Q., Feng, J., & Deng, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113722 · Cited by 7
Tocut, M., Shoenfeld, Y., & Zandman‐Goddard, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1807004 · Cited by 7
New Insights Into Systemic Lupus Erythematosus Therapies
Wang, D. H., & Wallace, D. J. (2020) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001603 · Cited by 7
New therapeutic approaches in systemic lupus erythematosus
Kolios, A. G. A., Yoshida, N., & Tsokos, G. C. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000772 · Cited by 7
Metadata
- Authors
- Lai, Z.-W., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Tily, H., Francis, L., Faraone, S. V., Phillips, P. E., & Perl, A.
- Affiliations
- SUNY Upstate Medical University (US)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 391
- Issue
- 10126
- Pages
- 1186-1196
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC5891154
- OpenAlex
- W2791734424
- Cited by
- 412
- References
- 43
- Citations by year
- 2026: 35 · 2025: 43 · 2024: 51 · 2023: 35 · 2022: 67 · 2021: 44 · 2020: 56 · 2019: 49 · 2018: 31
- FWCI
- 38.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Pfizer
- Syracuse University
- National Institute of Allergy and Infectious Diseases (R01AI048079, R01AI122176, R56AI048079, R01AI072648, R34AI141304)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- rapamycin, systemic lupus erythematosus, mTOR inhibition, T cell dysfunction, refractory lupus, disease activity, BILAG index, SLEDAI, drug safety and tolerability, biomarker-driven treatment, mTOR inhibitors, immunosuppressive therapy, dose adjustment, adverse events, lupus nephritis, proteinuria, thrombocytopenia
- MeSH terms
- Adolescent, Adult, Aged, Drug Tolerance, Female, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Treatment Outcome, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
